logo

Clovis Oncology, Inc. (CLVS)



Trade CLVS now with
  Date
  Headline
6/4/2018 6:03:58 AM Clovis Oncology Submits Application To EMA To Expand Marketing Authorization For Rubraca
5/29/2018 8:07:27 AM Clovis Oncology Announces European Commission Authorization Of Rubraca For Women With Recurrent Ovarian Cancer
4/16/2018 9:01:27 PM Clovis Oncology Announces Upsizing And Pricing Of Offering Of $300 Mln Amount Of 1.25% Convertible Senior Notes Due 2025
4/16/2018 6:45:27 AM Clovis Intends To Offer $200 Mln Of Convertible Senior Notes Due 2025 And $100 Million Of Shares Of Common Stock
3/23/2018 8:57:55 AM Clovis Oncology Says CHMP Grants Positive Opinion For Its Rubraca Tablets
2/27/2018 8:59:50 AM RBC Capital Markets Is Lowering Clovis Oncology, Inc. (CLVS) FY18 Rev. Estimate To 122.8 M From 131.5 M
2/27/2018 8:59:37 AM RBC Capital Markets Is Cutting Clovis Oncology, Inc. (CLVS) Q1 18 Rev. Estimate To 18.1 M From 19.6 M
2/27/2018 8:59:19 AM RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) FY19 Estimate To -1.64 From -2.02
2/27/2018 8:59:05 AM RBC Capital Markets Is Raising Clovis Oncology, Inc. (CLVS) FY18 Estimate To -5.34 From -5.65
2/27/2018 8:58:51 AM RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) Q1 18 Estimate To -1.39 From -1.46
2/27/2018 7:12:06 AM Sierra Oncology FY Net Loss $42.0 Mln Vs Net Loss Of $47.9 Mln Last Year
2/21/2018 5:13:39 PM Clovis Oncology Receives Positive Trend Vote From CHMP For Rucaparib Ovarian Cancer Treatment Indication
12/19/2017 8:07:03 AM Clovis :Rucaparib MAA For Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology